BFKW

Bariatric Medical Devicesbfkw.org

BFKW, LLC is a small Michigan-based medical-device developer of the Full Sense™ Device, a temporary implantable satiety-inducing weight-loss product. It is privately held, founded in 2004, and reliant on periodic securities offerings rather than disclosed commercial revenue.

Company typePrivate
Founded2004
HeadquartersGrand Rapids, United States
Headcount1–10
GTM typeB2B
OfferingHardware or Manufacturing

BFKW firmographics

Firmographics

Name: BFKW
Legal name: BFKW, LLC
Website: https://bfkw.org
Company type: Private
Founded year: 2004
Operating status: Operating
Headcount range: 1–10 employees
Short description: BFKW, LLC is a small Michigan-based medical-device developer of the Full Sense™ Device, a temporary implantable satiety-inducing weight-loss product. It is privately held, founded in 2004, and reliant on periodic securities offerings rather than disclosed commercial revenue.
Ownership category
akta.pro rank

Where BFKW is headquartered

Location

Headquarters

HQ city: Grand Rapids
HQ country: United States
HQ region: North America

Offices1 record

Markets served

BFKW business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Personnel, Technology or R&D, Supply Chain, Operations

Revenue model

Securities offering: The company conducts securities offerings including equity and pooled investment fund interests, with up to $12 million in securities available and $1.83 million already sold. The offering is scheduled to last more than one year.

BFKW product offering

Product offering

Core offering

BFKW develops and manufactures the Full Sense™ Device, a temporary implantable medical device designed to induce long-lasting satiety and produce significant weight loss in patients. The company is a small, privately held medical device firm based in Grand Rapids, Michigan, focused on bariatric treatment solutions for obesity.

Differentiator

Problem solved

Functional benefit

Companies that use BFKW

Customer profile

Ideal customer profiles1 record

BFKW technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

BFKW partnerships and signals

Strategic signal

Scale indicators1 record

BFKW competitors and assessment

Company assessment

Direct peers

Spatz FGIA: Spatz Medical makes the Spatz3 adjustable gastric balloon, an endoscopic temporary implant for weight loss. It is a direct peer in the temporary, endoscopically-delivered satiety/space-occupying obesity device category.
Obalon Therapeutics: Obalon developed a swallowable, gas-filled intragastric balloon system for weight loss. It is a direct peer competing for the minimally-invasive, temporary obesity device niche that BFKW's Full Sense Device also targets.
Allurion Technologies: Allurion develops a swallowable, procedureless gastric balloon for weight loss. It is the closest direct peer to BFKW, competing for the same non-permanent, minimally-invasive obesity device niche that targets patients seeking alternatives to bariatric surgery.
Aspire Bariatrics (AspireAssist): Aspire Bariatrics developed the AspireAssist, an endoscopically-implanted weight loss device. It is a direct peer in the category of temporary, endoscopically-delivered obesity intervention devices.
Reshape Lifesciences (formerly ReShape Lifesciences, now part of Biorad): Reshape Lifesciences markets the Lap-Band adjustable gastric banding system for surgical weight loss. It is a direct competitor in the implantable obesity device space, though its product is permanent rather than temporary like BFKW's Full Sense Device.

Broad incumbents

Johnson & Johnson (Ethicon): Through Ethicon, J&J is a broad incumbent in bariatric/metabolic surgical devices. While it does not offer a temporary satiety implant, it represents the established surgical obesity device market that BFKW would need to disrupt or partner with for commercial reach.
Medtronic: Medtronic is a broad incumbent in surgical and metabolic devices, including bariatric surgery tools. It is comparable as a potential strategic acquirer or distribution partner for BFKW's endoscopic implant category.
Apollo Endosurgery: Apollo Endosurgery (acquired by Boston Scientific) commercializes endoscopic obesity devices including the Orbera intragastric balloon. It competes in the same endoscopic obesity intervention category and was the broad incumbent leader before its acquisition.

Others

Novo Nordisk: Novo Nordisk markets Wegovy (semaglutide), the leading GLP-1 obesity drug. It is adjacent rather than directly competitive, but defines the pharmaceutical standard-of-care against which any obesity device (including BFKW's Full Sense Device) must compete for share of voice and reimbursement.
Eli Lilly: Eli Lilly markets Zepbound (tirzepatide) for obesity. Like Novo Nordisk, it is an adjacent rather than direct competitor, but its rapid commercial success in the obesity space sets the competitive baseline for weight loss efficacy expectations that BFKW's implant must meet or exceed.

Market position

Customer concentration

BFKW financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BFKW leadership team

Management profile

Number of profiles

Profiles3 records

BFKW funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BFKW M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BFKW

What does BFKW do?

Is BFKW a public or private company?

BFKW is a private company. It is classified as venture growth investor backed and is currently operating.

When was BFKW founded?

BFKW was founded in 2004. It employs 1 to 10 people.

Where is BFKW based?

BFKW is headquartered in Grand Rapids, United States, in the North America region.

How does BFKW make money?

One revenue line is on record: securities offering.

Who are BFKW's main competitors?

Direct peers on record are Spatz FGIA, Obalon Therapeutics, Allurion Technologies, Aspire Bariatrics (AspireAssist) and Reshape Lifesciences (formerly ReShape Lifesciences, now part of Biorad). Broad incumbents are Johnson & Johnson (Ethicon), Medtronic and Apollo Endosurgery. Others are Novo Nordisk and Eli Lilly.

Does BFKW have an API?

No public API is recorded for BFKW.